SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

zovegalisib

RLAY·Relay Therapeutics, Inc.
BULLISH
Drug Impact Rating5/10
Trial phase
Phase 3
Time to market
The Phase 3 ReDiscover-2 trial is expected to complete enrollment in mid-2027, meaning a potential FDA approval filing would likely follow in 2028 at the earliest.
Why 5/10
The next hard, dated catalyst is the ASH 2026 oral presentation of updated Phase 1/2 ReInspire data in vascular anomalies on December 14, 2026, followed by a company conference call with a regulatory update. This is not a pivotal readout or PDUFA decision; the main value driver (Phase 3 breast cancer) readout is more than 12 months away.
Actionable Insight BULLISH

The ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.

Price Chart

Loading chart...

Executive Summary

Zovegalisib is Relay Therapeutics' lead asset, a first-in-class allosteric, mutant-selective PI3K-alpha inhibitor in Phase 3 for PIK3CA-mutant HR+/HER2- metastatic breast cancer. It received FDA Breakthrough Therapy Designation in February 2026. Early clinical data showed a 43% objective response rate and median 11.1-month progression-free survival with a favorable safety profile that avoids the hyperglycemia typical of older PI3K-alpha inhibitors. The company has $849 million in cash (runway into 2029), strong institutional backing (FMR LLC, BlackRock, State Street all added significantly), and 18 analysts rate the stock a strong buy with a mean price target of $27.58 (50% upside). The next catalyst is an oral presentation at ASH on December 14, 2026, with updated vascular anomaly data and a regulatory update.

How It Works

Zovegalisib is an oral small molecule designed to selectively inhibit mutant forms of PI3K-alpha (PI3K-alpha), a protein that drives cancer cell growth. Unlike older PI3K-alpha inhibitors such as alpelisib and inavolisib, which block both normal and mutant PI3K-alpha and cause side effects like high blood sugar, zovegalisib selectively targets only the mutant form by binding to a different site on the protein. This selectivity is designed to preserve normal PI3K-alpha function and reduce toxicity.

Trial Status

Zovegalisib is in a global Phase 3 registrational trial (ReDiscover-2) testing zovegalisib + fulvestrant versus capivasertib + fulvestrant in PIK3CA-mutant, HR+/HER2- advanced breast cancer, which began enrollment in mid-2025 with enrollment expected to complete in mid-2027. A separate Phase 3 frontline trial in endocrine-sensitive patients is expected to initiate in early 2027. A Phase 1/2 ReInspire trial in vascular anomalies is ongoing, with updated data to be presented at ASH on December 14, 2026. A Phase 2 trial in PIK3CA-related overgrowth spectrum (PROS) is also enrolling.

The Two-Sided Case

▲ Bull Case6
Zovegalisib's mutant-selective allosteric mechanism is differentiated from approved PI3K-alpha inhibitors (alpelisib, inavolisib) and could offer better tolerability, especially less hyperglycemia, which has been a major limitation of the class.
Phase 1/2 ReDiscover data showed a 43% ORR and median 11.1-month PFS in heavily pre-treated patients, with FDA Breakthrough Therapy Designation validating the approach.
Massive institutional accumulation in Q2 2026: FMR LLC doubled to $376M, BlackRock $286M, State Street $189M, T. Rowe Price $144M, and new positions from Baker Bros., Westfield Capital, and Polar Capital.
Strong analyst consensus: 18 of 19 analysts rate Buy or Strong Buy, mean price target $27.58 (50% upside from $18.39).
$849M cash provides runway into 2029, eliminating near-term dilution risk.
Two shots on goal: breast cancer (large market) and vascular anomalies (rare disease with potential accelerated path).
▼ Bear Case5
Zovegalisib is still unapproved and faces a long development timeline; Phase 3 ReDiscover-2 enrollment completes mid-2027, with pivotal data likely in 2028 or later.
Competition is entrenched: alpelisib (Novartis), inavolisib (Roche), and capivasertib (AstraZeneca) are already approved in the same or overlapping indications.
Insider selling is notable: CEO Sanjiv Patel sold $872K in October and $913K in September, and a 6M-share block was sold by SVF Pauling in August.
The ASH December catalyst is for a smaller vascular anomaly indication, not the pivotal breast cancer trial, and the regulatory update may not provide a clear registration path.
Net loss widened to $81.7M in Q3 2026, and the company has no approved products and no revenue.

Upcoming Catalysts

  • ASH 2026 oral presentation of updated ReInspire data in vascular anomalies on December 14, 2026, with company call with regulatory update.
  • Phase 3 ReDiscover-2 enrollment completion expected mid-2027.
  • Phase 3 frontline breast cancer trial expected to initiate in early 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Relay Therapeutics, Inc. PRESS-RELEASE RLAY ·Originating report

Sources · 9

Hover a chip for the title
1 ir.relaytx.com2 biospace.com3 targetedonc.com4 stocktitan.net5 sec.gov6 en.wikipedia.org7 ascopubs.org8 relaytx.com9 manilatimes.net